BIOVIE INC.: JANE STREET GROUP, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Jane Street Group LLC amended its Schedule 13G filing with the SEC (accession 0001595888-26-000133) covering its stake in BioVie Inc., updating its previously reported beneficial ownership position. The filing was disclosed via SEC accession and reflects a change to the quantitative details of Jane Street's holdings rather than an initial position. BioVie is a clinical-stage biopharmaceutical company, and Jane Street's stake is a passive investment. The amendment matters because 13G updates signal shifts in institutional ownership that can affect float and sentiment in a thinly traded microcap. Investors will watch for the specific share count and percentage disclosed in the amended filing, and for any further 13G or 13D activity from other institutional holders.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
BioVie Inc., Jane Street Group, LLC